Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 65 for “"Antibody-drug Conjugates"”.
-
ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.
… and trastuzumab emtansine (T-DM1) are anti-HER2 antibody-drug conjugates (ADCs) which have shown robust efficacy for treating breast cancer. For both ADCs, however, we lack effective biomarkers to predict outcomes from pre-treatment samples. Methods: To unveil predictive biomarkers for ADCs, we …
-
Quantitative analysis of cellular processing of Antibody-Drug Conjugates
Antibody-Drug Conjugates (ADCs) are a promising therapeutic class which combines the potency of chemotherapeutic drugs with the specificity of a tumor targeting antibody. ADCs aim to reduce systemic toxicity and maintain or improve therapeutic efficacy. Once an ADC reaches a tumor and binds its …
-
The Development of Sulfatase-Cleavable Linkers for Antibody-Drug Conjugates
Antibody-Drug Conjugates (ADCs) are a rapidly growing class of anticancer agents comprising a small molecule cytotoxin and a monoclonal antibody (mAb). A covalent linker joins the two therapeutic components, the properties of which are crucial to the success of an ADC. Although cathepsin-cleavable …
-
Rationally designed aplyronine analogues for use in antibody-drug conjugates
… potency renders the aplyronines promising drug candidates. However, the scarcity and structural complexity of the aplyronines brings challenges in supplying material to enable these studies, and calls into question their viability as commercial targets. Based on structure–activity …
-
Designed analogues of the aplyronines for use in antibody-drug conjugates
… candidates for incorporation as payloads into antibody-drug conjugates provided the supply problem can be solved. Guided by structure-activity relationship (SAR) studies, a highly convergent route towards novel and simplified aplyronine structures has been designed. Routes to these function- …
-
The Development of Methods for Generating Fc-Conjugates and Antibody-Drug Conjugates
… and proteins, constitute a valuable class of drugs due to their high target specificity and their ability to modulate protein interactions (PPIs), which are often considered ‘undruggable’ by traditional small molecule drugs. Additionally, antibodies possess many beneficial characteristics, …
-
Development of a Novel Bioconjugation Platform for the Generation of Homogenous Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) are therapeutic entities which leverage the specificity of antibodies to selectively deliver potent cytotoxins to specific cell types, such as cancer cells. The pharmacology of an ADC is critically dependent on its stability, homogeneity, and drug-to-antibody ratio …
-
Synthesis and biological evaluation of auristatin-F recombinant antibody-drug conjugates for cancer therapy
… as a contribution to the emerging field of antibody-drug conjugate (ADC) therapeutics, in which novel ADCs were generated and biologically evaluated for therapeutic potential and specificity towards cancer cells. SNAP-tag site-directed conjugation was employed in order to overcome the …
-
The Development of Peroxide-Responsive Arylboronic Acids for Antibody-Drug Conjugates and Small-Molecule Prodrugs
… can be exploited for the targeted delivery of drugs. Section I of this thesis describes the design, synthesis, and evaluation of antibody-drug conjugates (ADCs) comprising arylboronic acid linkers, which give responsive drug release in the presence of the elevated hydrogen peroxide in cancer. …
-
FROM ANTIBODY-DRUG CONJUGATES TO MASKED ANTIBODIES: BIOPHYSICAL INSIGHT FOR THE RATIONAL DESIGN OF FUTURE THERAPIES
… years and, during this time, many successful antibody scaffolds have been based on wild-type humanized and human sequences of the immunoglobulin G isotype 1 (IgG1) subclass. In the past, several mutations have been engineered into these scaffolds, to optimise biological/physical properties or …
-
The Development of Divinyl-Heteroaryl Linkers for the Synthesis of Stable and Functional Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilise the exquisite selectivity of antibodies for membrane receptors to selectively deliver cytotoxic warheads to specific cell types, such as cancer cells. Much effort has been invested in recent years to deliver ADCs with …
-
CAR-T και Antibody–Drug Conjugates στη σύγχρονη ογκολογία: Φαρμακοεπαγρύπνηση, προφίλ ασφάλειας και προκλήσεις στην κλινική εφαρμογή και πρόσβαση
… θεραπείες, όπως οι κυτταρικές CAR-T και τα Antibody–Drug Conjugates, ADCs, που εμφανίζουν σημαντική ανταπόκριση τόσο στην αντιμετώπιση αιματολογικών κακοηθειών όσο και συμπαγών όγκων. Στην παρούσα εργασία, τονίζεται η σημαντικότητα των νέων ογκολογικών θεραπειών, αναλύοντας συγκεκριμένα …
-
Exploration of novel linker scaffolds enabling the simultaneous rebridging of disulfide bonds for the synthesis of antibody-drug conjugates
Antibody-drug conjugates (ADCs) are a class of targeted therapeutic, typically used for the treatment of cancers. By attaching drugs site-selectively to antibodies, off-target toxicity of the drug can be reduced, leading to significant benefits for the patient. In order to improve the homogeneity …
-
The Development of Vinylheteroarene Linkers for Proteinogenic Cysteine Modification and Studies Towards Applying (+)-Discodermolide as a Novel Payload in Antibody-Drug Conjugates
… (+)-Discodermolide as a Novel Payload in Antibody-Drug Conjugates Hikaru Seki Antibody-drug conjugates (ADCs) are an emerging class of anticancer agents which combine the cell-targeting properties of a monoclonal antibody and the cytotoxicity of a small molecule drug. The antibody, …
-
Αποτελεσματικότητα των συζευγμένων αντισωμάτων στον καρκίνο των ωοθηκών: Συστηματική ανασκόπηση και μετα-ανάλυση κλινικών δοκιμών φάσης II και III / Efficacy of antibody-drug conjugates in ovarian cancer: a systematic review and meta-analysis of phase ΙΙ and ΙΙΙ clinical trials
Εισαγωγή: Τα συζεύγματα αντισωμάτων (antibody–drug conjugates, ADCs) αποτελούν μια αναδυόμενη θεραπευτική προσέγγιση στον καρκίνο των ωοθηκών, συνδυάζοντας την ειδικότητα των μονοκλωνικών αντισωμάτων με την κυτταροτοξική δράση ισχυρών φαρμακευτικών παραγόντων. Οι υπάρχουσες μετα-αναλύσεις εστιάζουν …
-
Cysteine arylation
… fluorescent dyes, affinity and radio labels, drug molecules, and polymers and nanocomposites. These traditional reactions generate sulfur-sp³ carbon bonds between the cysteine thiol and the labeling reagents. The goal of this thesis is to develop new cysteine arylation reactions to generate …
-
Bioengineering functional polymer systems for glycan-based targeting and drug release
Bioengineering drug delivery facilitates re-potentiation of existing drugs and drug candidates, bypassing hurdles in novel drug development and accelerating the advance of medicine. Drug delivery strategies aim to enhance therapeutic effect by enhancing delivery to the target cells or tissues, …
Page 1 of 4